OncLive SOSS

HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice - Episode 12

Unmet Needs and Future Direction in HER2+ Breast Cancer

July 29, 2024

Joyce A. O'Shaughnessy, MD, Melinda L. Telli, MD, Aditya Bardia, MD, MPH, FASCO, Ian Krop, MD, PhD, Kandace McGuire, MD

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Challenges in Diagnosing HER2+ Breast Cancer

EP. 2: Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

EP. 3: Preoperative Monitoring and Surgical Options for HER2+ Patients

EP. 4: Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

EP. 5: Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

EP. 6: Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

EP. 7: Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

EP. 8: Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

EP. 9: Overview of DESTINY-Breast06

EP. 10: Clinical Perspectives on Managing ILD Related to T-DXd

EP. 11: Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

EP. 12: Unmet Needs and Future Direction in HER2+ Breast Cancer

Video content above is prompted by the following:

Please provide your closing thoughts about current and future management in HER2+ early stage mBC and HER2-low and ultra-low mBC.

x